Menu

Retractions Damage Scientists’ Reputations: Study

Authors of rescinded papers see a 10 percent to 20 percent decline in citation rates for their other publications. 

Sep 8, 2017
Aggie Mika

ISTOCK, KIZILKAYAPHOTOSLife science researchers who author retracted papers are perceived as less credible by their peers, according to a study published online last month (August 14) in Research Policy. On average, these scientists experienced a 10 percent dip in citations of their unaffected work following a retraction, the study finds. Meanwhile, prominent scientists—individuals who were highly cited or were raking in top funding at the time of the retraction—experienced a nearly 20 percent drop in citation rates.

“The mighty fall further, because they were standing taller to begin with,” coauthor Alessandro Bonatti of MIT Sloan School of Management says in a news release.

To understand how retractions affect the scientific community’s perception of researchers’ remaining publications, the authors of the current study examined citation rates for the bodies of work produced by both offending and retraction-free authors. The researchers assessed 23,620 publications by 376 scientists who had published papers between 1977 and 2007 that were later retracted. For their control group, the researchers also evaluated 46,538 publications, taken from in the same journals and written by 759 authors whose work had never been retracted.

“The question we’re asking is: Do retractions trigger, at an individual level, something like an infection mechanism, where the retracted author is being punished and discredited for being dishonest or just incompetent?” explains Bonatti. “We find that yes, there is such a mechanism in place, and it operates through citations.”

See “How Journals Treat Papers from Researchers Who Committed Misconduct

Bonatti and colleagues also assessed whether retractions resulted in harsher consequences for scientists in the upper echelons of their fields, and whether the motivation for the retractions—foul play, such as plagiarism, versus an honest mistake resulting from lab errors or statistical mishaps—had any affect on the perception of the offending scientists’ remaining work.

The authors found that the more renowned scientists suffered worse than their lesser-known counterparts; the reported declines in citations rates almost doubled for leading scientists. But, retractions only resulted in more-severe repercussions for elite researchers if the reason for the retraction stemmed from some sort of scientific malfeasance. “[T]he work of eminent authors is not penalized more severely than that of less eminent ones in the case of honest mistakes,” the authors write in their report.

See “Self Correction

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.